AMRN
Price
$15.21
Change
+$0.30 (+2.01%)
Updated
Jun 12, 02:48 PM (EDT)
Capitalization
313.49M
Intraday BUY SELL Signals
INBX
Price
$93.39
Change
-$0.15 (-0.16%)
Updated
Jun 12, 02:31 PM (EDT)
Capitalization
1.37B
68 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRN vs INBX

Header iconAMRN vs INBX Comparison
Open Charts AMRN vs INBXBanner chart's image
AMRN vs INBX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMRN vs. INBX commentary
Jun 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a StrongBuy and INBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 12, 2026
Stock price -- (AMRN: $14.95 vs. INBX: $93.42)
Brand notoriety: AMRN: Notable vs. INBX: Not notable
AMRN represents the Pharmaceuticals: Major, while INBX is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMRN: 68% vs. INBX: 73%
Market capitalization -- AMRN: $313.49M vs. INBX: $1.37B
AMRN [@Pharmaceuticals: Major] is valued at $313.49M. INBX’s [@Biotechnology] market capitalization is $1.37B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $1.04T to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $112.95B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $187.09B. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileINBX’s FA Score has 1 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • INBX’s FA Score: 1 green, 4 red.
According to our system of comparison, INBX is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 4 TA indicator(s) are bullish while INBX’s TA Score has 3 bullish TA indicator(s).

  • AMRN’s TA Score: 4 bullish, 5 bearish.
  • INBX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, AMRN is a better buy in the short-term than INBX.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а +8.33% price change this week, while INBX (@Biotechnology) price change was +2.38% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.59%. For the same industry, the average monthly price growth was +6.96%, and the average quarterly price growth was +4.95%.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.31%. For the same industry, the average monthly price growth was +80.35%, and the average quarterly price growth was +1823.74%.

Reported Earning Dates

INBX is expected to report earnings on Aug 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.59% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (+1.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INBX($1.37B) has a higher market cap than AMRN($313M). INBX YTD gains are higher at: 18.253 vs. AMRN (7.130). AMRN has higher annual earnings (EBITDA): -24.36M vs. INBX (-114.82M). AMRN has more cash in the bank: 308M vs. INBX (162M). AMRN has less debt than INBX: AMRN (5.59M) vs INBX (181M). AMRN has higher revenues than INBX: AMRN (217M) vs INBX (1.3M).
AMRNINBXAMRN / INBX
Capitalization313M1.37B23%
EBITDA-24.36M-114.82M21%
Gain YTD7.13018.25339%
P/E RatioN/A0.20-
Revenue217M1.3M16,692%
Total Cash308M162M190%
Total Debt5.59M181M3%
FUNDAMENTALS RATINGS
AMRN: Fundamental Ratings
AMRN
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMRNINBX
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
73%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 18 days ago
86%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AMRN
Daily Signal:
Gain/Loss:
INBX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APDJX19.950.51
+2.62%
Artisan International Small-Mid Advisor
PSPJX33.98N/A
N/A
Principal Large Cap S&P 500 Index J
HWAAX44.08N/A
N/A
Hotchkis & Wiley Value Opps A
GXXIX14.15N/A
N/A
abrdn US Sustainable Leaders InstlSvc
AGCWX20.91N/A
N/A
American Century Global Small Cap R